Sign In
Buy VERX
$12.98
+0.600 (+4.85%)
At Close: Jul 13, 2026
Here's What Key Metrics Tell Us About Vertex (VERX) Q4 Earnings
10:36am, Thursday, 27'th Feb 2025
The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Vertex (VERX) Tops Q4 Earnings and Revenue Estimates
09:25am, Thursday, 27'th Feb 2025
Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.13 per share a year ago.
Vertex Announces Fourth Quarter and Full Year 2024 Financial Results
07:05am, Thursday, 27'th Feb 2025
KING OF PRUSSIA, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial
Vertex to Report Q4 Earnings: What's in Store for the Stock?
11:56am, Monday, 24'th Feb 2025
VERX's fourth-quarter 2024 performance is likely to have benefited from the growing adoption of cloud-based tax automation solutions.
Countdown to Vertex (VERX) Q4 Earnings: Wall Street Forecasts for Key Metrics
10:22am, Monday, 24'th Feb 2025
Get a deeper insight into the potential performance of Vertex (VERX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for so
Vertex to Participate in Upcoming March Investor Conferences
04:05pm, Tuesday, 18'th Feb 2025
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President a
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing
04:35am, Friday, 14'th Feb 2025
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business.
Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX
07:30am, Thursday, 13'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDA
Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX
07:30am, Wednesday, 12'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDA
Calls of the Day: Charles Schwab, Vertex Pharma and Transocean
02:21pm, Tuesday, 11'th Feb 2025
The Investment Committee debate the latest Calls of the Day.
Vertex: Strong Sales, Stronger Pipeline
09:15am, Tuesday, 11'th Feb 2025
Here's our initial take on Vertex Pharmaceuticals' (VRTX 0.14%) fourth-quarter financial report.
Vertex's Revenue Surges but EPS Slips
05:56pm, Monday, 10'th Feb 2025
Vertex Pharmaceuticals (VRTX 0.14%), known for its innovative treatments, reported its fourth-quarter earnings on Feb. 10. The company's revenue increased significantly to $2.91 billion, which was abo
Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
04:40pm, Monday, 10'th Feb 2025
Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts' expectations.
Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
04:14pm, Monday, 10'th Feb 2025
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its cystic fibrosis drugs and early contributions from a newly approved non-opi
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
04:01pm, Monday, 10'th Feb 2025
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided its
